



Roadshow Presentation

March 2017

Disclaimer



- **THIS PRESENTATION, WHICH HAS BEEN PREPARED BY BANCA FARMAFACTURING S.P.A. (THE "COMPANY"), IS PRELIMINARY IN NATURE, AND IS SUBJECT TO UPDATING, REVISION AND AMENDMENT. THIS PRESENTATION MAY NOT BE REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE WITHOUT OUR CONSENT. THIS PRESENTATION DOES NOT PURPORT TO BE COMPREHENSIVE.**
- The information and opinions contained in this Presentation are provided as of 31 December 2016, are subject to change without notice and do not purport to contain all information that may be required to evaluate the Company. The information in this Presentation is in preliminary form and has not been independently verified. Neither the Company nor any of its affiliates and advisers, or any other party undertakes or is under any duty to update this Presentation or to correct any inaccuracies in any such information which may become apparent or to provide you with any additional information. No reliance may or should be placed for any purpose whatsoever on the information contained in this Presentation or on its completeness, accuracy or fairness. None of the foregoing persons accepts any responsibility whatsoever for the contents of this Presentation, and no representation or warranty, express or implied, is made by any such person in relation to the contents of this Presentation. To the fullest extent permissible by law, such persons disclaim all and any responsibility or liability, whether arising in tort, contract or otherwise, which they might otherwise have in respect of this Presentation. Recipients should not construe the contents of this Presentation as legal, tax, regulatory, financial or accounting advice and are urged to consult with their own advisers in relation to such matters.
- To the extent applicable, the industry and market data contained in this Presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry or market data contained in this Presentation.
- Certain information in this Presentation is based on management estimates. Such estimates have been made in good faith and represent the current beliefs of relevant members of management. Those management members believe that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete.
- This Presentation may include statements that are, or may be deemed to be, forward-looking statements. Forward-looking statements typically use terms such as "believes", "projects", "anticipates", "expects", "intends", "plans", "may", "will", "would", "could" or "should" or similar terminology. Any forward-looking statements in this Presentation are based on the Company's current expectations and, by their nature, forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause the Company's actual results and performance to differ materially from any expected future results or performance expressed or implied by any forward-looking statements. Statements contained in this Presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. You are cautioned not to place undue reliance on the forward-looking statements contained herein, which are made only as of the date of this Presentation.
- The Company undertakes no obligation to release the results of any revisions to any forward-looking statements in this Presentation that may occur due to any change in its expectations or to reflect events or circumstances after the date of this Presentation and the parties named above disclaim any such obligation.
- No reliance should be placed for any purposes whatsoever on the information contained in this Presentation or on its completeness. No representation or warranty, express or implied, is given by or on behalf of the Company or any of its directors, officers, advisers, agents or employees, or any other person as to the accuracy, truthfulness, fairness, materiality or completeness of the information or opinions contained in this Presentation. No liability whatsoever is accepted by the Company or any of its members, directors, officers, advisers, agents or employees for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

BFF Banking Group: A Bank Like No Other



Leading financial services provider to suppliers of the European Healthcare and Public Administration sectors

1	Market leader in large and underpenetrated markets	€240bn market
2	Solid and resilient business model with compelling assets and earning growth	>20% CAGR 2013-2016 ⁽¹⁾
3	Low risk profile coupled with solid capital position	10bps Cost of Risk 19.5% TC ratio ⁽²⁾ vs. 15% Target
4	Superior cash generation with proven track record of high profitability and dividend	37% RoTE ⁽¹⁾ 100% payout
5	Significant growth potential through excess capital, invested platform and access to funding	30% RWA growth & 100% payout €1bn of liquidity
6	Management fully aligned with shareholders	>7% direct stake post IPO 8% hurdle rate on stock options


Source: Annual Report

Notes: (1) 2013 income statement normalised for change in LPI accounting; 2016 net income, RoTE and C/I ratio adjusted to exclude extraordinary costs and including 12 months of Magellan. (2) Referring to Banking Group and pro forma for DBRS downgrade, 5% increase in LPI recovery rate and Tier II issuance.


Established presence in Italy, Spain and Portugal Expanded in CEE with the acquisition of Magellan



€240bn of Public Sector expenditures in the countries we operate in⁽¹⁾



26% of Customer Loans outside Italy⁽³⁾



- Established presence in Italy, Spain and Portugal
- Expanded in CEE with the acquisition of Magellan

Public expenditure in good and services (€bn)⁽²⁾
 BFF's ex Magellan markets
 Magellan current markets

Source: Eurostat

Notes: (1) Exchange rate as of 31/12/15; (2) Data as of 2015. (3) Data for Magellan are converted into EUR assuming an FX of 4.4103 (31/12/2016)

Leading Provider of Credit Management and Working Capital Solutions to Public Sector Suppliers, to Tackle the Payment Delays From the Public Administration in Italy, Iberia and CEE



Endemic Delay in Payments in the Public Sector

- Some European countries have endemic delays in payments due to Public Administration suppliers, because of:
 - 1 Mismatch between centralised tax collection and decentralised public spending
 - Only 16% of total public expenditure for goods and services in Italy is controlled by Central Government ⁽¹⁾
 - 2 Administrative complexity: 22,948 Italian public entities⁽²⁾, 18,838 Spanish public entities⁽³⁾ and 4,069 Portuguese public entities⁽⁴⁾
 - 3 Commercial debt not classified as public debt, allowing financial flexibility to governments
- Government interventions in Italy and Iberia have not been effective in reducing the delays on a long-term basis

What BFF Offers to Customer

- ✓ De-risking
- ✓ Certainty of collection
- ✓ Efficient processing
- ✓ Working capital optimisation
- ✓ Maintenance of good commercial relationship between customers and debtors

Source: Annual report, Assobiomedica, FENIN, Apifarma, DEF, CNE

Note (1) As of 2015, €134.1bn of total Italian Public spending for goods and services; (2) Source IPA, Indice delle Pubbliche Amministrazioni; (3) Source IGAE, Intervencion General de la Administracion del Estado; (4) Source Associação Nacional Municípios Portugueses, Direcção Geral do Orçamento and Comissão Nacional de Eleicoes


BFF's Services Offered




General Overview

- Three business lines:
- **Non Recourse Factoring (“Purchased”)** (Funded business, 82% of gross revenues⁽¹⁾)
- **Credit Collection Management** (Unfunded business, 4% of gross revenues⁽¹⁾)
- **Financing** to healthcare entities and Local Government in CEE (funded business, 12% of gross revenues⁽¹⁾)

Focus on Non-recourse Factoring - Revenues Model



Total New Business Volumes (€m)



Source: Annual Report

Notes: (1) Based on Banking Income gross of interest expenses and commission expenses (2) Data for Magellan are converted into EUR assuming an FX of 4.4103 (31/12/2016).


Solid Business Model

Suppliers


- ▶ Long-standing relationship with top suppliers to the PA (leading multinational and national suppliers) → top 10 clients have been BFF clients for more than 16 years
- ▶ Majority of clients have outsourced their credit management activities to BFF → significant barrier to entry
- ▶ Significant recurring business with established clients

BFF excl. Magellan Non-Recourse Volumes (€bn)

■ Recurring Clients ■ Other Clients




Recurring clients⁽¹⁾ represented on average more than 70% of total volume



- **Highly experienced senior management team with a long tenure in the Group (> 12 years)**



- **Advanced and scalable IT platform developed in-house**



Debtors

- ▶ Long track record in dealing with Public entities and deep knowledge of the payment dynamics → better collection
- ▶ A proprietary database built over 30 years of experience enabling for an accurate estimate of collection time and credit risk → better pricing
- ▶ Short term duration of the receivables purchased allowing constant repricing
- ▶ Negligible Cost of Risk
- ▶ Low risk of underlying receivables (commercial debt vs. sovereign debt)

(€bn) ⁽²⁾	ITA	SPA	POR
Commercial debt	49	15	2
Government debt	2,170	1,073	231

Investment Highlights

Leading franchise	1 <i>Leader in a Large Market With a Solid Business Model...</i>	<ul style="list-style-type: none"> ▪ Leading financial services supplier to the European Healthcare and PA sectors ▪ €240bn potential market, underpenetrated ▪ Significant recurring business from LT clients and long track record in dealing with Public entities
Attractive economics	2 <i>...Able to Deliver Growth...</i>	<ul style="list-style-type: none"> ▪ Customer loans ex-Magellan CAGR '13-'16: +22% ▪ 23% net income CAGR over the last 4 years ▪ Accretive acquisition of Magellan, accelerating geographical expansion
	3 <i>.. while Maintaining a Low Risk Profile ...</i>	<ul style="list-style-type: none"> ▪ 99% loan exposure to public and healthcare sector ▪ 0.5% net NPLs ratio / 10bps Cost of Risk ▪ Total Capital ratio of 19.5%⁽²⁾ (vs. management target of 15%) and CET1 more than 2.5x the SREP requirement (6.55% as of March 2017)
	4 <i>... and Efficient Cost Structure Despite Investments for Growth...</i>	<ul style="list-style-type: none"> ▪ 32% Cost / Income adjusted despite Magellan and investments in infrastructure to sustain further growth ▪ A growing and diversified funding base with potential for further funding efficiencies ▪ Further potential upside from funding synergies on Magellan
	5 <i>...and with High Visibility of Future Revenues from LPI</i>	<ul style="list-style-type: none"> ▪ €0.4bn off balance sheet late payment interest (“LPI”) reserve ▪ Accounting defers significant earnings: even with 0% volume growth, earning will grow
Self funded business	6 <i>High Profitability and Significant Free Capital Generation</i>	<ul style="list-style-type: none"> ▪ 2016 RoTE of 37%⁽³⁾ ▪ 100% pay-out ratio in 2016 with more than €230m dividend paid in the last 4 years ▪ Rich capital structure allows for growth and 100% dividend payout

Source: Assifact and company financial statement.

Notes: (1) computed based on data published in the press release and AR 2016 (2) Referring to Banking Group and pro forma for DBRS downgrade, 5% increase in LPI recovery rate and Tier II issuance. (3) adjusted to exclude extraordinary costs and including 12 months of Magellan.

1

We Operate in an Underpenetrated €240bn Market, with Leadership Position in Many Geographies...




Key Considerations


- Total potential market is the public sector expenditure in goods & services, c. €240bn in Italy, Poland, Spain, Portugal, Slovakia and Czech Republic
- In Southern Europe, stable market despite austerity measures
- Growing market in CEE

BFF Positioning

Non-recourse Factoring outstandings with PA & NHS (€7.3bn)







#1 Independent Player



• #1 Independent Player
 • Sole specialised player in Portugal

• Leader in alternative financing in Poland
 • Sole specialised player in Slovakia
 • One of the few specialist in Czech Republic

Total Public Expenditure in Goods and Service (€bn)





Source: PwC, IMF, DEF 2015 and 2016, Ministerio de Sanidad, Servicios Sociales e Igualdad, Ministerio de Hacienda y Administraciones Públicas, and Actualizacion del Programa de Estabilidad 2016-2019 - Reino de Espana, Instituto Nacional de Estadistica - Portugal
 Notes: (1) Total current public expenditure for goods and services; (2) Breakdown not available; (3) Calculated as percentage of total PA & NHS spending

... With a Growing Business, Increasingly Diversified...


Key Considerations

- Significant customer loans growth with an higher contribution from less capital intensive segments (non NHS public administration)
- Increased geographic diversification with strengthened exposures in non domestic markets

Customer Loans Evolution (€m)



Customer Loans Breakdown by Geography (%)




... And with Positive Trend in Revenues

Key Considerations

- Net banking income adjusted increased by 8% in 2016 to €175m (including Magellan and €2m financing costs)
- C.11% increase of net banking income for BFF only (net of one-off and financing costs of Magellan) thanks to higher average outstanding and to lower interest expense driven by a diversified funding base
- €20m Magellan stable contribution YoY


Net Banking Income⁽¹⁾ (€m)



Notes: (1) Including 12 months of Magellan for 2016 data and adjusted for extraordinary items; (2) €20 Magellan NBI (i) includes €12m relative to the 7 months post BFF's acquisition (as in BFF reported consolidated accounts) and (ii) pro-forma for €8m relative to the 5 months before the acquisition

A Solid Business Model Able to Grow Profitably through Every Storm...

Net Income (2007-2016)



Source: annual reports, Factset


(1) 2013 and 2014 net income normalised for change in LPI accounting (2) Excluding €11m of extraordinary expenses and including €4m Magellan 5 months contribution (3) Adjusted to exclude extraordinary costs

... Thanks to Our Fortress Balance Sheet and Low Risk Profile...

Key Considerations


- A fortress balance sheet positively geared to an increase in interest rates
- Commercial receivables funded through a well diversified funding base and with a short maturity allowing for fast re-pricing
- Conservative asset / liability management approach: funding duration higher than that of receivables
- LPI at a rate of Central Bank base rate +8%
- €361m of LPI stock off-balance sheet represents a further buffer
- Low leverage (4.9% leverage ratio Pillar III)
- Low risk profile
 - High creditworthiness of the counterparties: 99% loan exposure to public and healthcare sector
 - Net NPLs ratio at 0.5%
 - Negligible credit risk: CoR constantly close to zero even after Magellan acquisition

Breakdown of Balance Sheet YE2016 (€m)



Cost of Risk (bps)

NPL ratio




Source: Annual report and press release

Notes: (1) €334m of equity plus €262m of off-balance sheet unrecognised LPI post tax (assuming 27.5% tax rate). (2) Interest income on average loans (3) Including dividend to be paid in 2017 on net income 2016 (4) Including €95m bond of Magellan (5) Based on 2016 number including Magellan for 12 months (i.e. -€2.7m of total provisions)

... Backed by a Strong Capital Position

- Robust capital position maintained also after the cash acquisition of Magellan, the full 2016 net income pay-out and DBRS Italian downgrade
 - Total Capital ratio pro forma of 19.5%^(1,2), +4.5% vs 15.0% company target** and substantially above SREP of 10.75% Total Capital (vs. previous requirement of 13.0%)
 - CET1 ratio pro forma of 14.1%, more than 2.0x the SREP requirement of 6.55% CET1** (previous requirement of 7.3%)⁽²⁾
- Conservative RWA calculation** (based on standard model and with the Italian exposure to NHS and other PA risk weighted at 100%)⁽¹⁾
- Capital position ready to continue to deliver **growth and dividend**
 - On 21st of February 2017, BFF issued €100m Tier 2 bond to support business expansion
 - The 4.5% excess capital** allows BFF to growth the RWA by 30% while maintaining a 100% dividend payout
 - After that, the high RoTE of the business allows strong RWA growth with high dividend payout

Banking Group ex. TUB Capital Ratios Evolution⁽³⁾



Note: (1) Following the DBRS downgrade the capital ratios will be calculated based on the higher risk weighting factor (from 50% to 100%) for the Italian exposure to NHS and other PA different from local government starting from March 2017; (2) CRR CET1 ratio equal to 16.4% and CRR Total Capital ratio equal to 16.6%; (3) Estimated impacts on CET1 arising from DBRS Italian downgrade (-3.6%, impact only on Italian exposure to NHS and other PA different from local government which moved from 50% to 100%), 5% increase in the LPI recovery rate (+1.0%) and Tier II issuance (+5.4%)

Source: Company data.


Invested in the Business while Maintained Strong Efficiency




Key Considerations

- Banca Farmafactoring heavily invested over the last three years in infrastructure and people **to support growth**
- Managed to maintain an efficient cost structure with **best in class Cost / Income ratio around 30%** - also post **Magellan acquisition**
- **Ca. €13m gross extraordinary costs in 2016**: c.€3.5m related to BFF IPO, ca. €2.2m extraordinary contribution to Resolution Fund and the rest for the Magellan acquisition
- Cost increase mainly driven by (i) personnel expenses due to **new hires also for Magellan and increased MBO accrual** due to higher than budgeted results, (ii) administrative costs related to **increased business activities and group structure**

Number of employee and Cost / Income ratio



Operating Costs Adjusted for Extraordinary Items (€m)



Notes: (1) Adjusted to exclude extraordinary costs; (2) C/I computed as operating expenses (administrative expenses + staff expenses + amortization on tangible and intangible assets) divided by net banking income; (3) Adjusted to exclude extraordinary costs. For 2015 adjusted net income includes ca. €0.3m ordinary contribution to Fondo Interbancario and Resolution Fund and excludes €0.7m of extraordinary contribution to Resolution Fund


Source: Company data

Diversified Funding Base with Potential for Further Funding Cost Optimization


Key Considerations

- A growing and diversified funding base (2x from 2013):
 - €817m online deposits raised in Italy, Spain and Germany as of year-end 2016, up ca. 90% vs. year-end 2015
 - **Strong liquidity position** with a LCR above 500% as of December 2016
- **Reduction in cost of funding** with an average cost of funding, for BFF only, of 1.7% vs. 4.9% in 2013
 - Additional €150m 5 years Senior Unsecured bond issued in June 2016 at 1.25% interest rate. €300m senior unsecured bond at a fixed rate of 2.75% expiring in June 2017, that can be comfortably refinanced with available lines
- **Further potential upside from funding synergies on Magellan: 4.4% Magellan cost of funding vs. 1.7% for BFF only**

Available Funding⁽¹⁾ (€m)



Interest Expenses (€m)




5 High Visibility of Future Revenues from LPI

Key Considerations


- The full impacts on BFF's P&L originated by the LPIs and related to the significant growth of purchased receivables over the last years will be fully visible only in the coming years:
 - A LPI on current outstandings and on already collected receivables generate revenues for 5 years (€33m deferred as of 31 Dec)
 - B The full P&L impact related to a higher LPI recovery rate vs. the assumed 40% (45% since 2017) will become visible only at collection date of the LPI

Illustrative example




Notes: (1) Assuming 40% of recovery rate

LPI Stock Evolution (Excl. Magellan) (€m)





Outstanding Evolution (Excl. Magellan) (€m)



High Profitability and Significant Free Capital Generation ...

Key Considerations

- Almost doubled net income^(1,2) in the last 4 years to €88m (incl. Magellan)
- Significantly improved return on capital thanks to an efficient use of capital
 - 2016 RoTE adjusted combined at 37%
 - ROTE consistently above 20% over the last 4 years
- Historical attractive dividend flows despite strong RWA growth with **more than €240m dividend paid between 2013 – 2016 and with a pay-out ratio of over 95% on average and 16% CAGR**
- Attractive dividend flow confirmed also in 2016 despite cash acquisition of Magellan, Italian downgrade and significant extraordinary costs for IPO and M&A



Notes: (1) Throughout the document, P&L data for Magellan are converted into EUR assuming an FX of 4.3632 (average Jan-Dec 2016) and Balance Sheet data are converted into EUR assuming an FX of 4.4103 (Dec 2016); (2) Adjusted to exclude extraordinary costs. For 2015 adjusted net income includes ca. €0.3m ordinary contribution to Fondo Interbancario and Resolution Fund and excludes €0.7m of extraordinary contribution to Resolution Fund. (3) 2013 and 2014 net income pro-forma for change in LPI accounting (4) Reported (5) Net income adjusted for €11m extraordinary costs and €4m for 5 months Magellan contribution

Source: Company data

RoTE: 37%

Total Capital ratio: 19.5%

Target Total Capital ratio: 15%

1

Invested in the
business for
growth ...

Significant investment in infrastructure
and expanded employee base to support
business expansion

2

... with plenty of
funding ...

Ample liquidity (€1bn at year end) and
access to multiple deposit and wholesale
markets

3

... and raised
capital to grow

4.5% of excess capital after the Tier II
issuance to self fund growth while
maintaining 100% payout ratio

Highly capital generative model able to self fund
superior growth and deliver attractive dividend
as already proven over the last years:

- The 19.5% total capital ratio allows full net income distribution until RWA grow by 30%
- Given its high RoTE, BFF can maintain both high growth and high payout ratio after full deployment of the excess capital

Management Fully Aligned With Public Market Shareholders

Management have been shareholders of the business since 2006
Senior executives have been in the bank for more than 12 years

Yearly management bonus

- ✓ Paid only if budget achieved, zero otherwise
- ✓ 50% in shares or stock options
- ✓ Multiplied up to 140% if EBTDA risk adjusted is +10% or higher than budget

Large direct stock ownership

- ✓ Management will have a > 7% stake post IPO (31 shareholders)
- ✓ None of the manager will own more than 5%
- ✓ 1 year lock up
- ✓ All manager shareholders have non compete agreement

Stock options with 8% hurdle rate

- ✓ 3.75% pool allocated at IPO
- ✓ Strike price equal to IPO price + 8% compounded returns
- ✓ 3 years vesting
- ✓ Broad coverage throughout the organisation (60+ people)

Key Takeaway



1	Market leader in large and underpenetrated markets	€240bn market
2	Solid and resilient business model with compelling assets and earning growth	>20% CAGR 2013-2016 ⁽¹⁾
3	Low risk profile coupled with solid capital position	10bps Cost of Risk 19.5% TC ratio ⁽²⁾
4	Superior cash generation with proven track record of high profitability and dividend	37% RoTE 100% payout
5	Significant growth potential through excess capital, invested platform and access to funding	30% RWA growth €1bn of liquidity
6	Management fully aligned with shareholders	>7% direct stake post IPO 8% hurdle rate on stock options

Source: Annual Report

Notes: (1) 2013 income statement normalised for change in LPI accounting; 2016 net income, RoTE and C/I ratio adjusted to exclude extraordinary costs and including 12 months of Magellan. (2) Referring to Banking Group and pro forma for DBRS downgrade, 5% increase in LPI recovery rate and Tier II issuance.


APPENDIX

2016 Net Income Reconciliation

Key Considerations


- **Reported net income equal to ca. €72m**, including net income from Magellan (7 months only)
- **Reported net income highly impacted by extraordinary expenses that will not be recurring from 2017 onwards**
- **Adjusted net income equal to ca. €88m**, adjusted for:
 - 1 **€1.5m of extraordinary contribution** (post tax) to Resolution Fund
 - 2 **€10.0m of extraordinary items (post tax)**, including €2.4m related to BFF IPO and remaining €7.6m extraordinary expenses related to Magellan acquisition
 - 3 **€4.0m related to Magellan net income** (January to May period)
 - And including:
 - €1.1m cost related to ordinary contribution to “Fondo Interbancario” and Resolution Fund
 - €1.4m financing cost (post tax) related to Magellan acquisition costs

Net Income Adjusted and Combined Build-up (€m)



History

Long and Successful Track Record in a Changing Environment



Magellan: The Story of a Successful Acquisition



Key Acquisition Highlights

BFF demonstrated a disciplined approach to acquisition enabling to acquire Magellan for a total cash consideration of €103m ...

...revealing a successful acquisition with 2015 P/E of 10.0x for a business with high RoTE...

...and strong synergies potential

Execution Highlights

- ✓ Increased geographic diversification: 25% of 2016 outstanding amount outside of Italy vs. 11% in 2015
- ✓ Consideration fully paid in cash and no equity raise involved
- ✓ Boosted Group RoTE adjusted up to 37% in 2016⁽¹⁾⁽²⁾, from 28% in 2015 (BFF only)
- ✓ Tangible Magellan contribution to BFF Group Net Income
- ✓ Further funding synergies coming from the optimisation of Magellan's source of funding (4.4% CoF of Magellan in IVQ 2016 vs. 1.8% of BFF standalone in 2H 2016⁽³⁾)

Notes: (1) Throughout the document, P&L data for Magellan are converted into EUR assuming an FX of 4.3632 (average Jan-Dec 2016) and Balance Sheet data are converted into EUR assuming an FX of 4.4103 (Dec 2016); (2) Adjusted to exclude extraordinary costs. For 2015 adjusted net income includes ca. €0.3m ordinary contribution to Fondo Interbancario and Resolution Fund and excludes €0.7m of extraordinary contribution to Resolution Fund (3) Including the effect of EUR/PLN swap for PLN IC Loan
Source: Company data


Traditional Business Subject to Seasonality, with Peak in Q4

BFF excl. Magellan


Key Considerations

- Business subject to a certain degree of seasonality, due to customers' preference in selling receivables towards the end of the quarter (especially in 4Q)
- On average ca. 60% purchased in the 2H with the peak of purchases in the last three months
- Outstanding accumulated in the last quarter of the year offers high level of visibility on revenues in the following years

Breakdown of Volumes by Quarter⁽¹⁾ (€bn)



Outstanding Evolution by Quarter (BFF Excl. Magellan) (€m)



Notes: (1) Excluding Magellan

Growing Loan Portfolio with Significant Contribution from Italy



■ NHS ■ P.A. ■ Other


○ Delta '16-15

Notes: (1) Including Magellan for 2015


Further Potential Upside from Funding Synergies on Magellan

Magellan Funding Structure


- BFF Group's strategy aims to optimise Magellan's local cost of funding to bring it in line with BFF (process already started in second half of 2016)
 - Significant portion of EUR denominated funding already refinanced by BFF Group
 - For PLN denominated funding, BFF Group started renegotiation of the existing funding lines and structured new banking facilities at a lower cost
- Funding synergies will also come from maturing of Magellan bonds to be refinanced with cheaper funding instruments



Cost of funding (BFF + Magellan - %)



Bond Maturity Profile



Note: (1) PLN floating assuming Wibor 6m of 1.80%; (2) EUR/PLN 4.4103, EUR Fixed at 3.80% swapped in PLN to finance Magellan SA Polish business

Scenario analysis: Purchased volumes always constant

P&L impacts - Illustrative example

	Y1	Y2	Y3	Y4	Y5	Y6	Y7
Purchased	100	100	100	100	100	100	100
Outstanding loans	100	100	100	100	100	100	100
<i>Growth %</i>	0%	0%	0%	0%	0%	0%	0%
Maturity commissions	6.0	6.0	6.0	6.0	6.0	6.0	6.0
LPI in P&L	2.6	2.8	3.0	3.3	3.6	3.6	3.6
<i>LPI accrued on Y1 purchased</i>	2.6	0.2	0.3	0.3	0.3	-	-
<i>LPI accrued on Y2 purchased</i>		2.6	0.2	0.3	0.3	0.3	-
<i>LPI accrued on Y3 purchased</i>			2.6	0.2	0.3	0.3	0.3
<i>LPI accrued on Y4 purchased</i>				2.6	0.2	0.3	0.3
<i>LPI accrued on Y5 purchased</i>					2.6	0.2	0.3
<i>LPI accrued on Y6 purchased</i>						2.6	0.2
<i>LPI accrued on Y7 purchased</i>							2.6
Funding costs	(2.4)	(2.4)	(2.4)	(2.4)	(2.4)	(2.4)	(2.4)
Total accrued revenues	6.2	6.4	6.7	7.0	7.3	7.3	7.3
Over recovery upon LPI collection (@ 60%)					1.2	1.2	1.2
NBI	6.2	6.4	6.7	7.0	8.5	8.5	8.5
Net income	2.8	2.9	3.0	3.2	3.9	3.9	3.9
<i>Growth</i>		4%	4%	4%	22%	0%	0%
Dividend	2.8	2.9	3.0	3.2	3.9	3.9	3.9
<i>Payout</i>	100%	100%	100%	100%	100%	100%	100%

P&L pre over recovery on LPI

CAGR Y1 - Y6:
7%

Tot. dividend
over period:
ca. €23m

Comments

- **Scenario assumption: no growth in outstanding over the period considered**
 - Outstanding at Y0: **€100K**
 - Receivable assumed to be purchased 1st January
 - Assumed **average financial in balance sheet (days): 365**
 - Assumed **maturity commission fee: 6%**
 - Assumed **cost of funding: 2.5%**
 - Assumed collection period for LPI from the purchase: **1,800 days**
 - Assumed **LPI interest rate: 8.05%** (8% + ECB rate 5bps)
 - Assumed **IRR : ca. 9%**
 - **C/I ratio constant at 32%**
 - **Cost of risk assumed at 10bps**
 - **LPI recovery rate at 45%** and over collection at **15%** (60% total LPI recovery rate)
 - Assumed **CET1 at 12%** and **RWA density at 75%**

Assumptions as per Analyst Presentation

Scenario analysis: Growth in purchased volumes in year 2 and flat afterward

P&L impacts - Illustrative example

	Y1	Y2	Y3	Y4	Y5	Y6	Y7	Y8
Purchased	100	130	130	130	130	130	130	130
Outstanding loans	100	130	130	130	130	130	130	130
Growth %	0%	30%	0%	0%	0%	0%	0%	0%
Outstanding growth of c. 30% in Y2								
Maturity commissions	6.0	7.8	7.8	7.8	7.8	7.8	7.8	7.8
LPI in P&L	2.6	3.6	3.9	4.2	4.6	4.7	4.7	4.7
LPI accrued on Y1 purchased	2.6	0.2	0.3	0.3	0.3	-	-	-
LPI accrued on Y2 purchased		3.3	0.3	0.3	0.4	0.4	-	-
LPI accrued on Y3 purchased			3.3	0.3	0.3	0.4	0.4	-
LPI accrued on Y4 purchased				3.3	0.3	0.3	0.4	0.4
LPI accrued on Y5 purchased					3.3	0.3	0.3	0.4
LPI accrued on Y6 purchased						3.3	0.3	0.3
LPI accrued on Y7 purchased							3.3	0.3
LPI accrued on Y8 purchased								3.3
Funding costs	(2.4)	(3.1)	(3.1)	(3.1)	(3.1)	(3.1)	(3.1)	(3.1)
Total accrued revenues	6.2	8.3	8.6	9.0	9.4	9.5	9.5	9.5
Over recovery upon LPI collection (@ 60%)					1.2	1.6	1.6	1.6
NBI	6.2	8.3	8.6	9.0	10.6	11.0	11.0	11.0
Net income	2.8	3.8	3.9	4.1	4.8	5.0	5.0	5.0
Growth		34%	4%	4%	18%	4%	0%	0%
Dividend	2.8	1.1	3.9	4.1	4.8	5.0	5.0	5.0
Payout	100%	28%	100%	100%	100%	100%	100%	100%

Assuming net income of the period invested in the RWA growth

Comments

- Scenario assumption: growth in outstanding of c. 30% in Y2 and flat afterwards
 - Outstanding at Y0: €100K
 - Receivable assumed to be purchased 1st January
 - Assumed average financial in balance sheet (days): 365
 - Assumed maturity commission fee: 6%
 - Assumed cost of funding: 2.5%
 - Assumed collection period for LPI from the purchase: 1,800 days
 - Assumed LPI interest rate: 8.05% (8% + ECB rate 5bps)
 - Assumed IRR : ca. 9%
 - C/I ratio constant at 32%
 - Cost of risk assumed at 10bps
 - LPI recovery rate at 45% and over collection at 15% (60% total LPI recovery rate)
 - Assumed CET1 at 12% and RWA density at 75%

Assumptions as per Analyst Presentation

P&L pre over recovery on LPI

Scenario analysis: Growth in purchased volumes in year 2 and 3, flat afterward

P&L impacts - Illustrative example

	Y1	Y2	Y3	Y4	Y5	Y6	Y7	Y8
Purchased	100	130	160	160	160	160	160	160
Outstanding loans	100	130	160	160	160	160	160	160
Growth %	0%	30%	23%	0%	0%	0%	0%	0%
Maturity commissions	6.0	7.8	9.6	9.6	9.6	9.6	9.6	9.6
LPI in P&L	2.6	3.6	4.7	5.1	5.5	5.7	5.8	5.8
LPI accrued on Y1 purchased	2.6	0.2	0.3	0.3	0.3	-	-	-
LPI accrued on Y2 purchased		3.3	0.3	0.3	0.4	0.4	-	-
LPI accrued on Y3 purchased			4.1	0.4	0.4	0.4	0.5	-
LPI accrued on Y4 purchased				4.1	0.4	0.4	0.4	0.5
LPI accrued on Y5 purchased					4.1	0.4	0.4	0.4
LPI accrued on Y6 purchased						4.1	0.4	0.4
LPI accrued on Y7 purchased							4.1	0.4
LPI accrued on Y8 purchased								4.1
Funding costs	(2.4)	(3.1)	(3.8)	(3.8)	(3.8)	(3.8)	(3.8)	(3.8)
Total accrued revenues	6.2	8.3	10.5	10.9	11.4	11.5	11.6	11.6
Over recovery upon LPI collection (@ 60%)					1.2	1.6	1.9	1.9
NBI	6.2	8.3	10.5	10.9	12.6	13.1	13.6	13.6
Net income	2.8	3.8	4.7	4.9	5.7	6.0	6.2	6.2
Growth		34%	26%	4%	16%	4%	4%	0%
Dividend	2.8	1.1	2.0	4.9	5.7	6.0	6.2	6.2
Payout	100%	28%	43%	100%	100%	100%	100%	100%

Assuming net income of the period invested in the RWA growth

Comments

- Scenario assumption: growth in outstanding to €130m in Y2 and €160m in Y3 and flat afterwards
- Outstanding at Y0: €100K
- Receivable assumed to be purchased 1st January
- Assumed average financial in balance sheet (days): 365
- Assumed maturity commission fee: 6%
- Assumed cost of funding: 2.5%
- Assumed collection period for LPI from the purchase: 1,800 days
- Assumed LPI interest rate: 8.05% (8% + ECB rate 5bps)
- Assumed IRR : ca. 9%
- C/I ratio constant at 32%
- Cost of risk assumed at 10bps
- LPI recovery rate at 45% and over collection at 15% (60% total LPI recovery rate)
- Assumed CET1 at 12% and RWA density at 75%

Assumptions as per Analyst Presentation

Summary Profit & Loss



€ '000	31-Dec-2013	Pro-forma ⁽¹⁾ 31-Dec-2014	31-Dec-2015 Reported BFF only	31-Dec-2016 Reported Group (consolidating only 7 months for Magellan)	31-Dec-2016 Group (consolidating 12 months for Magellan and excluding extr. costs)
Interest Income	154,643	151,968	161,946	190,225	204,022
Interest Expenses	(53,644)	(44,240)	(28,898)	(31,020)	(37,142)
Net Interest Income	100,999	107,729	133,048	159,205	166,880
Net Fee and Commission Income	9,164	8,239	7,943	3,355	6,845
Dividends	0	0	0	60	123
Gains/Losses on Trading	1,701	497	46	682	666
Gains/Losses on Hedging	0	(7)	(23)	(1)	(1)
Gains/Losses on Purchase / Disposal of Available- for-Sale Financial Assets	0	953	872	706	706
Net Banking Income	111,864	117,411	141,886	164,007	175,219
Impairment Losses/Reversals on Financial Assets	(1,136)	131	(1,126)	(2,244)	(2,678)
Administrative Expenses	(30,278)	(35,954)	(45,567)	(63,642)	(53,519)
Net Adjustments to/ Writebacks on Property, Plant and Equipment and Intangible Assets	(1,789)	(1,743)	(2,138)	(2,616)	(2,729)
Provisions for risks and charges	(734)	(1,280)	(879)	(2,075)	(2,076)
Other Operating Income (Expenses)	6,609	7,032	4,144	5,704	6,112
Profit Before Income Taxes from Continuing Operations	84,537	85,597	96,320	99,134	120,330
Income Taxes	(35,624)	(28,129)	(27,529)	(26,997)	(32,761)
Net Income	48,913	57,468	68,791	72,137	87,569

Source: Company data (1) Pro-forma 2014 figures calculated as if new LPI methodology had been adopted since FY2011

Summary Historical Balance Sheet



€ '000	31-Dec-2013	31-Dec-2014	31-Dec-2015 Reported BFF only	31-Dec-2016
Assets				
Cash and Cash Balances	1	3	160	149
Financial Assets Held for Trading	5	0	0	244
Financial Assets at Fair Value	0	0	0	3,401
Available-for-Sale Financial Assets	82,015	370,180	429,438	385,280
Financial Assets Held to Maturity		955,932	822,859	1,629,320
Due from Banks	325,944	97,726	60,523	144,871
Receivables and Loans	1,136,578	1,554,957	1,962,004	2,499,094
Hedging derivatives	0	0	0	529
Equity Investments	0	0	0	302
Property, Plant and Equipment	12,829	12,693	12,666	12,988
Intangible Assets	1,122	2,053	2,747	25,811
Tax Assets	40,083	31,117	28,053	25,870
Other Assets	9,336	2,106	3,106	7,137
Total Assets	1,607,913	3,026,767	3,321,556	4,734,996
Liabilities and Equity				
Due to Banks	804,451	968,264	688,081	634,807
Due to Customers	173,438	1,168,587	1,726,683	2,996,142
Securities Issued	320,000	468,562	452,962	634,283
Financial Liabilities Held for Trading	548	46	0	7
Hedging derivatives	0	47	0	176
Tax Liabilities	47,016	73,057	70,583	73,659
Other Liabilities	25,370	32,377	45,885	54,319
Employee Severance Indemnities	705	717	883	867
Provisions for Risks and Charges	3,377	4,316	5,195	6,989
Equity	184,096	186,416	262,493	261,610
Profit for the Year	48,913	124,378	68,791	72,137
Total Liabilities and Equity	1,607,913	3,026,767	3,321,556	4,734,996

Source: Company data